July 11th, 2017 Natixis Partners advised Synerlab Group, the niche pharmaceutical manufacturing expert controlled by 21 Centrale Partners, for the refinancing of its existing debt
Synerlab refinanced its existing debt by setting up a new €M 160 financing arranged and subscribed by its current partner ICG together with Goldman Sachs. Synerlab will benefit from additional financial resources to finance its future industrial investments and to pursue its external growth strategy, including via a strategic acquisition in Europe which could be completed in the coming months.
Founded in 2001 and taken over by 21 Centrale Partners in 2013, Synerlab Group is a leading European player in the pharmaceutical manufacturing sector. The group with 6 production sites and 1000 employees supports its clients, from renowned pharmaceutical laboratories, in the development, manufacture and packaging of medicines in various galenic forms. Synerlab Group’s sales have grown by 30% thanks to an optimized structuring, the improvement of its product range positioned on buoyant niche markets, an increase in its production capacity through organic growth and the opening of new markets through external growth.‹ Back to news
Debt Advisory Team: